Department of Neurosurgery, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str, 22, 81675, Munich, Germany.
BMC Cancer. 2013 Feb 2;13:51. doi: 10.1186/1471-2407-13-51.
Today, the treatment of choice for high- and low-grade gliomas requires primarily surgical resection to achieve the best survival and quality of life. Nevertheless, many gliomas within highly eloquent cortical regions, e.g., insula, rolandic, and left perisylvian cortex, still do not undergo surgery because of the impending risk of surgery-related deficits at some centers. However, pre and intraoperative brain mapping, intraoperative neuromonitoring (IOM), and awake surgery increase safety, which allows resection of most of these tumors with a considerably low rate of postoperatively new deficits.
Between 2006 and 2012, we resected 47 out of 51 supratentorial gliomas (92%), which were primarily evaluated to be non-resectable during previous presentation at another neurosurgical department. Out of these, 25 were glioblastomas WHO grade IV (53%), 14 were anaplastic astrocytomas WHO grade III (30%), 7 were diffuse astrocytomas WHO grade II (15%), and one was a pilocytic astrocytoma WHO grade I (2%). All data, including pre and intraoperative brain mapping and monitoring (IOM) by motor evoked potentials (MEPs) were reviewed and related to the postoperative outcome.
Awake surgery was performed in 8 cases (17%). IOM was required in 38 cases (81%) and was stable in 18 cases (47%), whereas MEPs changed the surgical strategy in 10 cases (26%). Thereby, gross total resection was achieved in 35 cases (74%). Postoperatively, 17 of 47 patients (36%) had a new motor or language deficit, which remained permanent in 8.5% (4 patients). Progression-free follow-up was 11.3 months (range: 2 weeks - 64.5 months) and median survival was 14.8 months (range: 4 weeks - 20.5 months). Median Karnofsky Performance Scale was 85 before and 80 after surgery).
In specialized centers, most highly eloquent gliomas are eligible for surgical resection with an acceptable rate of surgery-related deficits; therefore, they should be referred to specialized centers.
目前,高级别和低级别脑胶质瘤的治疗选择主要需要手术切除,以实现最佳生存和生活质量。然而,由于一些中心存在手术相关缺陷的潜在风险,许多位于高度语言功能区的脑胶质瘤,如脑岛、 Rolandic 区和左侧大脑外侧裂周围皮质,仍未进行手术。然而,术前和术中脑区定位、术中神经监测(IOM)和唤醒手术可提高安全性,这使得大多数此类肿瘤得以切除,术后新出现缺陷的比率相当低。
2006 年至 2012 年间,我们切除了 51 例幕上胶质瘤中的 47 例(92%),这些肿瘤之前在另一家神经外科就诊时被评估为无法切除。其中,25 例为胶质母细胞瘤 WHO 分级 IV(53%),14 例为间变星形细胞瘤 WHO 分级 III(30%),7 例为弥漫性星形细胞瘤 WHO 分级 II(15%),1 例为毛细胞型星形细胞瘤 WHO 分级 I(2%)。所有数据,包括术前和术中脑区定位和监测(通过运动诱发电位[MEPs]进行 IOM),都进行了回顾,并与术后结果相关联。
8 例(17%)患者行唤醒手术。38 例(81%)需要 IOM,18 例(47%)IOM 稳定,10 例(26%)MEPs 改变手术策略。因此,35 例(74%)患者实现了大体全切除。术后,47 例患者中有 17 例(36%)出现新的运动或语言缺陷,其中 8.5%(4 例)为永久性缺陷。无进展生存期为 11.3 个月(范围:2 周至 64.5 个月),中位生存期为 14.8 个月(范围:4 周至 20.5 个月)。术前 Karnofsky 表现量表评分为 85,术后为 80。
在专业中心,大多数高度语言功能区脑胶质瘤有资格进行手术切除,且手术相关缺陷的发生率可接受;因此,这些肿瘤应转诊至专业中心。